Allison L. Naleway

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway et al. · MMWR Morbidity and Mortality Weekly Report · 2021 · 794 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Nicola P. Klein, Ned Lewis, Kristin Goddard et al. · JAMA · 2021 · 641 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway et al. · New England Journal of Medicine · 2021 · 525 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

Mark G. Thompson, Edward Stenehjem, Shaun J. Grannis et al. · New England Journal of Medicine · 2021 · 507 citations · Full text

Veterinary Medicine, Emergency Medicine, Infectious Diseases +17

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon et al. · MMWR Morbidity and Mortality Weekly Report · 2022 · 476 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17